OM DENNE EPISODE
Professor Francesco Del Galdo and Professor Yannick Allanore discuss two recent studies advancing the treatment landscape in scleroderma. This episode discusses tofacitinib efficacy and neutrophil-driven vasculopathy in SSc. Through expert-led discussion, this podcast offers practical perspectives for clinicians looking to stay at the forefront of scleroderma care.
To explore the full papers and download accompanying slide decks, visit the Scleroderma Forum. Stay up to date with the latest research and monthly podcast episodes through this free independent resource: www.scleroderma-forum.com
To explore the full papers and download accompanying slide decks, visit the Scleroderma Forum. Stay up to date with the latest research and monthly podcast episodes through this free independent resource: www.scleroderma-forum.com
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af Scleroderma Forum.
ANDRE EPISODE I DENNE PODCAST
Join Professors Francesco Del Galdo from the University of Leeds, and Chris Denton from UCL, as they discuss the role of autoantibodies in scleroderma.
Join Professors Francesco Del Galdo and Elisabetta Renzoni, Doctor Elizabeth Volkmann and Clinical Nurse Specialist Jean Scopes as they discuss the key takeaways from our recent 'Harnessing the Power of the Multidisciplinary Team in Scleroderma' webinar.
Join Professors Francesco Del Galdo, Christopher Denton and Yannick Allanore as they discuss the key takeaways from our recent 'The Role of Autoantibodies in SSc' webinar.
Join Professors Francesco Del Galdo and Zsuzsanna McMahan as they review their highlights of the recent ACR 2025 congress, watch them discuss their abstracts and highlight key information.
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra Scleroderma Forum, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
